Infex Therapeutics, an anti-infectives specialist, has raised £4.3 million in funding led by Jon Moulton, with participation from the GM&C Life Sciences Fund and existing high net worth investors. Infex Therapeutics develops novel anti-infectives targeting antimicrobial resistance and other critical-priority infectious diseases.
The funding will support preparation for further clinical development of RESP-X following completion of its Phase 2a trial in Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients. Expansion of the MET-X programme will continue alongside Infex Therapeutics’ clinical development partnership with Venus Remedies Ltd in India. Proceeds will also support progression of preclinical programmes, including a BamA inhibitor being developed in collaboration with Justus-Liebig-University Giessen.
RESP-X targets Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients, while the MET-X programme is focused on resistance bypass treatments for drug-resistant Gram-negative Enterobacterales infections. Preclinical work also includes first-in-class approaches targeting highly resistant Gram-negative pathogens.
Commenting on the investment, Dr Peter Jackson said the funding enables further development across RESP-X, MET-X and the broader preclinical pipeline. Jon Moulton said RESP-X is approaching a critical inflection point following the Phase IIa trial and described the programme as a potential future therapy for patients with drug resistant Pseudomonas aeruginosa colonisation.
We are delighted to secure this investment led by Jon Moulton, with support from the Greater Manchester and Cheshire Lifescience Investment Fund and our existing investors. This funding represents strong validation of our progress in developing novel anti-infectives to address the critical global threat of antimicrobial resistance. It enables us to advance RESP-X toward later stage clinical development, expand our MET-X programme, and advance our broader preclinical pipeline of first-in-class approaches targeting highly resistant Gram-negative pathogens.
We have supported Infex from the beginning and continue to be impressed by the Company’s scientific progress and strategic execution. Infex’s lead programme RESP-X is approaching a critical inflection point with upcoming phase IIa results, and we strongly believe it will be a life-changing future first therapy for NCFB patients with drug resistant Pa colonisation. This additional investment reflects our strong conviction in both the team and its innovative approach to tackling antimicrobial resistance.
Infex Therapeutics has made excellent scientific progress since we first invested several years ago. The company has clearly established itself as a world leader in the AMR and related space and the data it is generating is very compelling.
